About C-MER MEDICAL Company

We are one of the leading ophthalmology service providers in Hong Kong and Guangdong, China, founded under the “Himalin Shunchao” brand in January 2012. Headquartered in Hong Kong, China, we have expanded rapidly since our inception and became the first foreign investor to set up a wholly owned eye hospital in China. According to Frost & Sullivan's report, as of the last practical date, the Shenzhen Himalin Shunchao Eye Hospital, which we established in March 2013, was the first and only Hong Kong-funded private hospital established under the Closer Economic and Trade Partnership Arrangement (CEPA). With our pioneer advantage and our experience in providing world-class ophthalmology services in Hong Kong, China, to treat all common and difficult eye conditions, we believe we have established a leading eye hospital in Shenzhen. According to the “Patient Satisfaction” quarterly survey conducted by the Shenzhen Health and Family Planning Commission, Shenzhen Hima Hospital ranked third out of 113 public and private hospitals in Shenzhen in 2016 (the whole year), and ranked second in the first quarter of 2017. Furthermore, we plan to expand our business to North China through the establishment of Beijing Hima Hospital (which is expected to commence operation in the second half of 2017). The group was founded in January 2012 by Dr. Lam Shun-chiu, an ophthalmologist with over 30 years of clinical experience, in Hong Kong, China, with the aim of providing high-quality ophthalmology services. Since then, the Group has developed rapidly. Its network includes an ophthalmology center and four satellite clinics located at different strategic locations in Hong Kong, China. The fifth satellite clinic is expected to open in the second half of 2017. According to Frost & Sullivan's report, in terms of revenue, our Hong Kong clinic, Himalin Shun Chao Ophthalmology Center in Hong Kong, China, was the second largest ophthalmology center in the Hong Kong private ophthalmology service market in 2016, with a market share of 4.7%, and from 2014 to 2016, we had the highest revenue growth rate among the five major ophthalmology service providers in Hong Kong, China, achieving a compound annual growth rate of 29.6%. We believe that Shenzhen Hima Hospital has also been a success. According to Frost & Sullivan's report, in 2016, Shenzhen Hima Hospital ranked third in revenue in the private ophthalmology service market in Guangdong Province, with a market share of 5.4%. We provide diagnosis and treatment services for eye diseases such as cataracts, corneal and surface diseases, glaucoma, vitreoretinal and macular diseases, and adjuvant treatment of eye diseases with traditional Chinese medicine. According to Frost & Sullivan's report, in 2016, in the eye disease treatment market, Shenzhen Hima Hospital ranked second among private eye hospitals in Guangdong, with a market share of 8.7%. Our business is led by two ophthalmologists with management experience and supported by other management professionals. For example, Dr. Lam Shun-chiu and Dr. Lee Yu-wing not only have more than 20 years of clinical experience, but have also held management roles in various medical institutions and organizations (such as the Hong Kong Eye Hospital and the Hong Kong Society of Ophthalmology). Guided by a physician-led management team, we are able to focus our work on the quality of care services and patient experience, and invest resources to enable our ophthalmologists and physicians to abide by international standards of professionalism, ethics, and sense of responsibility in providing services. We are also committed to recruiting qualified ophthalmologists and physicians to form a comprehensive medical team. As of the last practical date, we have 8 ophthalmologists from Hong Kong, China, and 22 Chinese doctors, 3 of whom are overseas ophthalmologists living in China. We believe that in the near future, China's middle and high-end ophthalmology service market will usher in huge opportunities for development. According to Frost & Sullivan's report, China's ophthalmology services market reached RMB 82.7 billion in 2016, and is expected to grow at a compound annual growth rate of 14.0% over the five-year period from 2016 to 2021. Furthermore, according to the Frost & Sullivan report, the size of China's private ophthalmology services market is estimated to reach RMB 32.8 billion in 2021, or a compound annual growth rate of 18.4% over the same period. With our past success, we believe we are well-positioned to seize this growth opportunity and benefit from the rapid expansion of the Chinese ophthalmology services market in the near future. As part of our business strategy, we plan to further expand our service network in Hong Kong, China, and strategically cover China's first-tier cities and cities in the Guangdong-Hong Kong-Macao Greater Bay Area.